和黄医药在中国启动HMPL-760治疗复发/难治性弥漫性大B细胞淋巴瘤的III期临床试验

美股速递
Mar 23

和黄医药(HUTCHMED)近日宣布,已在中国正式启动HMPL-760针对复发或难治性弥漫性大B细胞淋巴瘤患者的III期临床试验。该试验旨在评估这一创新疗法在特定患者群体中的安全性和有效性,标志着公司在该疾病领域研发的重要进展。

弥漫性大B细胞淋巴瘤作为常见的恶性淋巴瘤类型,其复发或难治病例的治疗选择有限,临床需求迫切。此次III期试验的开展,有望为患者提供新的潜在治疗方向,并进一步巩固和黄医药在肿瘤创新药物研发领域的战略布局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10